BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Neutral 60.4%

Neg 0% Neu 60.4% Pos 0%

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.